Orrick Advises Catalyst Biosciences, Inc. on Follow-On Offering


Orrick advised Catalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, on its follow-on offering of 5,307,692 shares of common stock. The gross proceeds to Catalyst Biosciences, Inc. from the offering were approximately $34.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Catalyst Biosciences, Inc. Raymond James & Associates, Inc. acted as the sole book-running manager and JonesTrading Institutional Services LLC, Chardan and LifeSci Capital LLC acted as co-managers for the offering. The offering closed on February 18, 2020.

The Orrick team advising Catalyst Biosciences, Inc. was led by capital markets partners Stephen Thau and Niki Fang and included associates Kelly Mink and Sean Carfi.